Ventyx Biosciences (VTYX) Projected to Post Earnings on Tuesday

Ventyx Biosciences (NASDAQ:VTYX) is expected to release its earnings data before the market opens on Tuesday, February 25th. Analysts expect Ventyx Biosciences to post earnings of ($0.54) per share for the quarter.

Ventyx Biosciences Trading Up 1.8 %

Shares of VTYX stock opened at $1.71 on Tuesday. The company has a market capitalization of $120.92 million, a price-to-earnings ratio of -0.72 and a beta of 0.52. The firm has a 50-day moving average price of $2.11 and a 200 day moving average price of $2.17. Ventyx Biosciences has a twelve month low of $1.57 and a twelve month high of $11.48.

Insider Buying and Selling

In related news, insider John Nuss sold 21,119 shares of Ventyx Biosciences stock in a transaction on Friday, December 27th. The stock was sold at an average price of $2.36, for a total value of $49,840.84. Following the transaction, the insider now owns 464,582 shares in the company, valued at approximately $1,096,413.52. This trade represents a 4.35 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Raju Mohan purchased 261,752 shares of the stock in a transaction on Monday, November 25th. The shares were purchased at an average cost of $2.01 per share, with a total value of $526,121.52. Following the transaction, the chief executive officer now owns 2,175,028 shares of the company’s stock, valued at $4,371,806.28. This trade represents a 13.68 % increase in their position. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 630,000 shares of company stock valued at $1,262,415. Insiders own 18.18% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on VTYX shares. Oppenheimer reissued an “outperform” rating and issued a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. HC Wainwright reaffirmed a “neutral” rating on shares of Ventyx Biosciences in a research note on Tuesday, January 14th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $10.00.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.